Literature DB >> 11055896

Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.

G A Bellus1, E B Spector, P W Speiser, C A Weaver, A T Garber, C R Bryke, J Israel, S S Rosengren, M K Webster, D J Donoghue, C A Francomano.   

Abstract

The fibroblast growth factor-receptor 3 (FGFR3) Lys650 codon is located within a critical region of the tyrosine kinase-domain activation loop. Two missense mutations in this codon are known to result in strong constitutive activation of the FGFR3 tyrosine kinase and cause three different skeletal dysplasia syndromes-thanatophoric dysplasia type II (TD2) (A1948G [Lys650Glu]) and SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans) syndrome and thanatophoric dysplasia type I (TD1) (both due to A1949T [Lys650Met]). Other mutations within the FGFR3 tyrosine kinase domain (e.g., C1620A or C1620G [both resulting in Asn540Lys]) are known to cause hypochondroplasia, a relatively common but milder skeletal dysplasia. In 90 individuals with suspected clinical diagnoses of hypochondroplasia who do not have Asn540Lys mutations, we screened for mutations, in FGFR3 exon 15, that would disrupt a unique BbsI restriction site that includes the Lys650 codon. We report here the discovery of three novel mutations (G1950T and G1950C [both resulting in Lys650Asn] and A1948C [Lys650Gln]) occurring in six individuals from five families. Several physical and radiological features of these individuals were significantly milder than those in individuals with the Asn540Lys mutations. The Lys650Asn/Gln mutations result in constitutive activation of the FGFR3 tyrosine kinase but to a lesser degree than that observed with the Lys540Glu and Lys650Met mutations. These results demonstrate that different amino acid substitutions at the FGFR3 Lys650 codon can result in several different skeletal dysplasia phenotypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055896      PMCID: PMC1287918          DOI: 10.1086/316892

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  37 in total

1.  Observations suggesting allelism of the achondroplasia and hypochondroplasia genes.

Authors:  V A McKusick; T E Kelly; J P Dorst
Journal:  J Med Genet       Date:  1973-03       Impact factor: 6.318

2.  Hypochondroplasia. A report of five kindreds.

Authors:  R K Beals
Journal:  J Bone Joint Surg Am       Date:  1969-06       Impact factor: 5.284

3.  Hypochondroplasia.

Authors:  B A Walker; J L Murdoch; V A McKusick; L O Langer; R K Beals
Journal:  Am J Dis Child       Date:  1971-08

Review 4.  The chondrodystrophies.

Authors:  D L Rimoin
Journal:  Adv Hum Genet       Date:  1975

5.  Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online.

Authors:  H Kitoh; S G Brodie; K G Kupke; R S Lachman; W R Wilcox
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

6.  Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia.

Authors:  G Grigelioniené; O Eklöf; E Laurencikas; B Ollars; N T Hertel; J P Dumanski; L Hagenäs
Journal:  Acta Paediatr       Date:  2000-09       Impact factor: 2.299

7.  A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia.

Authors:  A Winterpacht; K Hilbert; C Stelzer; T Schweikardt; H Decker; H Segerer; J Spranger; B Zabel
Journal:  Physiol Genomics       Date:  2000-01-24       Impact factor: 3.107

8.  Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.

Authors:  G A Bellus; M J Bamshad; K A Przylepa; J Dorst; R R Lee; O Hurko; E W Jabs; C J Curry; W R Wilcox; R S Lachman; D L Rimoin; C A Francomano
Journal:  Am J Med Genet       Date:  1999-07-02

9.  Achondroplasia and hypochondroplasia. Clinical variation and spinal stenosis.

Authors:  R Wynne-Davies; W K Walsh; J Gormley
Journal:  J Bone Joint Surg Br       Date:  1981

10.  Hypochondroplasia: clinical and radiological aspects in 39 cases.

Authors:  B D Hall; J Spranger
Journal:  Radiology       Date:  1979-10       Impact factor: 11.105

View more
  39 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  Disproportionate stature but normal height in hypochondroplasia.

Authors:  Felix G Riepe; Nils Krone; Wolfgang G Sippell
Journal:  Eur J Pediatr       Date:  2005-03-15       Impact factor: 3.183

Review 3.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

4.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

Review 5.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

6.  Comparative X-ray morphometry of prenatal osteogenesis imperfecta type 2 and thanatophoric dysplasia: a contribution to prenatal differential diagnosis.

Authors:  Maria Pia Bondioni; Ugo Ernesto Pazzaglia; Claudia Izzi; Giuseppe Di Gaetano; Francesco Laffranchi; Maurizia Baldi; Federico Prefumo
Journal:  Radiol Med       Date:  2017-07-03       Impact factor: 3.469

Review 7.  Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin.

Authors:  Laura M McDonell; Kristin D Kernohan; Kym M Boycott; Sarah L Sawyer
Journal:  Hum Mol Genet       Date:  2015-07-07       Impact factor: 6.150

8.  Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

Authors:  G Sonvilla; S Allerstorfer; C Heinzle; S Stättner; J Karner; M Klimpfinger; F Wrba; H Fischer; C Gauglhofer; S Spiegl-Kreinecker; B Grasl-Kraupp; K Holzmann; M Grusch; W Berger; B Marian
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

9.  Cracking the molecular origin of intrinsic tyrosine kinase activity through analysis of pathogenic gain-of-function mutations.

Authors:  Huaibin Chen; Zhifeng Huang; Kaushik Dutta; Steven Blais; Thomas A Neubert; Xiaokun Li; David Cowburn; Nathaniel J Traaseth; Moosa Mohammadi
Journal:  Cell Rep       Date:  2013-07-18       Impact factor: 9.423

10.  Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.

Authors:  Anne Goriely; Ruth M S Hansen; Indira B Taylor; Inge A Olesen; Grete Krag Jacobsen; Simon J McGowan; Susanne P Pfeifer; Gilean A T McVean; Ewa Rajpert-De Meyts; Andrew O M Wilkie
Journal:  Nat Genet       Date:  2009-10-25       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.